Fibromyalgia Clinical Study Information


The Resonator™ device uses electro-magnetic stimulation in order to relieve symptoms of a disorder or disease.

 

Please Download the latest version of Adobe Flash Player.

 

ABOUT US

Our Team

Participate in our research
News Releases

Terms & Conditions of Use

 
 
 
 
   
   

Standardization Phase: 3 Days

Following baseline assessment, a subject will enter the 3 consecutive day standardization phase that requires the subject to commence recording his or her daily pain intensity rating, and to commence standardization and recording of usage of pain and insomnia medication(s), as needed, to his or her 30-day prior use pain and insomnia medication(s), as determined during study qualification evaluation. The subject will record the following in the Subject Daily Diary, as indicated below.

  1. Daily Pain Ratings: The subject will record his or her current degree of overall pain rating on the 0-10 Numeric Pain Intensity Scale upon waking each morning, prior to taking his or her first dose of permissible pain medication for the day. The subject may take a dose of his or her permissible pain medication immediately following recording of this morning pain rating, as needed
  2. Rescue Pain Medication Use: The subject will record each time that he or she takes a dose of the study permissible rescue pain medication.
  3. Insomnia Medication Use: The subject will record each time that he or she takes a dose of the study permissible insomnia medication.
  4. Concomitant Medication and Therapy Use: The subject will record each use of concomitant medications and therapies.

Following completion of the 3-day standardization phase, the subject will fax his or her completed daily subject diary to the testing site for evaluation by the sub-PI. Based on this evaluation, subject continued study participation is determined according to the following criteria:

  1. The subject‟s 3-recording average of degree of pain ratings in the Subject Daily Pain Diary for the standardization phase is at least 4 on the 0-10 Numeric Pain Intensity Scale.
  2. The subject did not take a pain medication dose prior to recording each of the 3 morning standardization phase pain ratings.
  3. The subject has refrained from consuming any non-approved medication indicated for the relief of pain or insomnia during the 3-day standardization phase.

If any of the above conditions are not satisfied, the subject will be disqualified from further participation in the study at this point.

The average of the subject‟s 3 daily pain ratings recorded on the 0-10 Numeric Pain Intensity Scale during the standardization phase will serve as the subject‟s baseline pain intensity rating.


 
 

4700 140th Ave. N., Suite 101 • Clearwater, FL 33762 • 727-474-3722

HOME | CONTACT US

 
 

The Resonator™ device is an Investigational Device limited by Federal (or United States)
law to investigational use. The Resonator™ device is not for sale, nor is the Magneceutical®
Therapy generally available outside of Investigational Review Board (IRB) approved clinical studies.